TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05146427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slow-wave enhancement
Description: A headband that measures slow-wave activity during sleep and uses auditory stimulation to enhance slow waves using closed-loop auditory stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: A headband that measures slow-wave activity during sleep but has no auditory stimulation.
Study: NCT04797182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: avatrombopag,60 mg/d,po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: avatrombopag,60 mg/d,po
Study: NCT05554367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study: NCT05370521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active dosage form taken once daily.
Study: NCT06152913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HANDS-ON treatment
Description: The HANDS-ON treatment consists of three phases:~Phase I (preparatory phase, 3 weeks) entails motivation for and commitment to treatment (including meaning in life), collaboration with parents and school professionals, setting individual treatment goals, preparing related exposure exercises. Phase II (intensive phase, 4 weeks) contains intensive, therapist-assisted exposure in a child's natural environment. Phase III (consolidation, 2 weeks) consists of continuation of exposure and consolidation. In this phase, there are weekly sessions with the therapist.
Study: NCT05056142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Anesthesia
Description: Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Analgesia
Description: Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
Study: NCT04828161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensovibep
Description: IV on day 1 only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensovibep
Description: IV on day 1 only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensovibep
Description: IV on day 1 only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensovibep
Description: IV on day 1 only.
Study: NCT06254001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion will be added at doses of 150 mg to 300 mg per day in addition to nicotine replacement therapy, counseling and cognitive behavioral therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy (Nicotine patches)
Description: Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (Nicotine patches)
Description: Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy
Study: NCT04828161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV on day 1 only.
Study: NCT05280366

Intervention type: DEVICE
Group type: OTHER
Intervention: Streamline Surgical System
Description: Completion of the Streamline Surgical System procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent Inject W
Description: Implantation of competitor device
Study: NCT05554367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT05370079

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Collection of biological sample (blood and/or CSF)
Description: Blood sample will be collected one time for each patient:~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube~If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).
Study: NCT06502535

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 15 g inulin once daily for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium nitrate and inulin
Description: 1300 mg potassium nitrate once daily for 4 weeks and 15 g inulin once daily for 4 weeks.
Study: NCT05915390

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: walnuts
Description: walnuts will provide 15% of the total energy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Habitual diet
Description: continue with habitual diet and abstain from walnuts
Study: NCT06169124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo archived tissue and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT
Study: NCT06169098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure on the left ear
Description: Auricular acupressure is applied at the Kidney point on the left ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure on the left ear
Description: Auricular acupressure is applied at the Kidney point on the left ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure on the right ear
Description: Auricular acupressure is applied at the Kidney point on the right ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure on the right ear
Description: Auricular acupressure is applied at the Kidney point on the right ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham auricular acupressure
Description: Sham auricular acupressure is applied at Kidney point on the left ear using a tape without any seed. After placement on this acupoint, apply consistent moderate pressure for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham auricular acupressure
Description: Sham auricular acupressure is applied at Kidney point on the left ear using a tape without any seed. After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
Study: NCT04400526

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A video competition
Description: Each Individual/group will be required to produce a maximum of 2-minute video on one of the following themes: (1) the hazardous effects of drug especially less psychotropic drugs such as Cannabis, (2) encouraging messages to drug abusers, and (3) existing anti-drug services.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A training workshop
Description: The workshop will last for 6 hours, and will be delivered by an experienced counsellor from C.H.O.I.C.E. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A mass promotional campaign
Description: Children who complete the training workshop in phase 2 will be invited to join phase 3. They are encouraged to design their own promotional activities for community members in the targeted districts. The activities can be delivered by a group (a maximum of 5 ADAs per group) or by an individual. Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites. Likewise, if the ADAs encounter any drug abuser in their social circles, the ADAs will be asked to deliver a brief advice based on the AWARD model.
Study: NCT06169124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05151731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamikibart
Description: Vamikibart will be administered by IVT injection as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamikibart
Description: Vamikibart will be administered by IVT injection as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamikibart
Description: Vamikibart will be administered by IVT injection as specified in each treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
Study: NCT05536102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: 20mg/m2, day 1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2, day 1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, days 1-14, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg, day 1, q3w
Study: NCT06451822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mIntense L+AS
Description: The investigated dermal filler mIntense L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
Study: NCT04846764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological tests
Description: Scales and tests to evaluate:~* laterality~* anxiety~* depression~* professional level~* education level~* pre-morbid level~* memory disorders~Experimental procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Scales and tests to evaluate:~* laterality~* anxiety~* depression~* professional level~* education level~* pre-morbid level~* memory disorders~Experimental procedure
Study: NCT05791890

Intervention type: DRUG
Intervention: Gilteritinib
Description: observational study to evaluate the incidence of infections during therapy with Gilteritinb

Intervention type: DRUG
Intervention: Gilteritinib
Description: observational study to evaluate the incidence of infections during therapy with Gilteritinb
Study: NCT04737330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
Study: NCT06112054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clotild Smart Guidewire System (CSGS)
Description: In the current study, a commercially available CE marked guidewire will be used to direct a catheter through blood vessels while the Clotild® Smart Guidewire (study device) will only be used to perform electrophysiological measurements (via its sensors) in the blood vessels during peripheral endovascular procedures. It is thus designed for use as an adjunct to conventional angiographic procedure
Study: NCT04996628

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Test 1
Description: Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Test 2
Description: Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Test 3
Description: Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
Study: NCT06188520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8421
Description: CDK2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8421
Description: CDK2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8421
Description: CDK2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8421
Description: CDK2 inhibitor
Study: NCT06348433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet is a formula diet with high fat, low carbohydrate, proper amount of protein and other nutrients.
Study: NCT06188520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: SERD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: SERD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: SERD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK4/6 inhibitor
Study: NCT04669535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AXO-AAV-GM2 Starting Dose
Description: 1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AXO-AAV-GM2 Low Dose
Description: 1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AXO-AAV-GM2 Middle Dose
Description: 1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AXO-AAV-GM2 High Dose
Description: 1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
Study: NCT05582694

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421
Description: UB-421 is a genetically engineered IgG1/kappa humanized monoclonal antibody with binding specificity to the human CD4 receptor complex. The dose of UB-421 will be 5 mg/kg given by intravenous infusion every 1 weeks for a total of 26 doses.
Study: NCT04857502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-based PSMA Imaging and Surgery Agent
Description: Given via IV injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study: NCT04929210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.
Study: NCT05272384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT04929210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as subcutaneous injection.
Study: NCT05205317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Sustained-release Tablets
Description: drug

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal repair
Description: The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal repair
Description: The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
Study: NCT06470295

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline will be infused during insulin-induced hypoglycemia
Study: NCT05272384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT06470295

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline will be infused during insulin-induced hypoglycemia

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C-peptide
Description: C-peptide will be infused during insulin-induced hypoglycemia

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C-peptide
Description: C-peptide will be infused during insulin-induced hypoglycemia
Study: NCT05040087

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensification of diabetes medication based largely on HbA1c levels
Description: Use of diabetes Rx in controls will be guided largely by HbA1c levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensification of diabetes medication based on glucose levels
Description: Use of diabetes Rx in the intensive Rx groups will be guided by participants' self-monitored blood glucose levels (SMBG), with management aimed to keep glucose levels within the normal range.
Study: NCT06068231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary Crown
Description: Implants were loaded with temporary restorations 6 to 8 weeks after implantation and had occlusal contact with opposing dentition.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent Crown
Description: Implants were loaded with permanent restorations at least 3 months after implantation and had occlusal contact with opposing dentition.